Literature DB >> 16533162

NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions.

H-H Tai1, H Cho, M Tong, Y Ding.   

Abstract

NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) catalyzes the oxidation of 15(S)-hydroxyl group of prostaglandins and lipoxins resulting in the formation of 15-keto metabolites which exhibit greatly reduced biological activities. Therefore, this enzyme has been considered the key enzyme responsible for the inactivation of prostaglandins and lipoxins. Both the cDNA and the genomic DNA of the 15-PGDH gene have been cloned. Structural characterization, transcriptional regulation and biological functions of this enzyme have been investigated. Molecular modeling corroborated with site-directed mutagenesis has identified key residues and domains involved in coenzyme and substrate binding. Catalytic mechanism has been proposed. Studies on the regulation of enzyme expression and activity by physiological and pharmacological agents have begun to uncover its significant roles in cancer, inflammation and reproduction. Apparently, 15-PGDH works with cyclooxygenase-2 to control the cellular levels of prostaglandins. Their reciprocal regulation within the same cells appears to determine the fate of the cells. Because of its ability to inactivate both prostaglandins and lipoxins of two opposite biological activities, the roles of 15-PGDH in cancer and inflammation are particularly intriguing and challenging. Future investigations in these areas are warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533162     DOI: 10.2174/138161206776055958

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  45 in total

1.  A Deep Insight Into the Sialotranscriptome of the Chagas Disease Vector, Panstrongylus megistus (Hemiptera: Heteroptera).

Authors:  José M C Ribeiro; Alexandra Schwarz; Ivo M B Francischetti
Journal:  J Med Entomol       Date:  2015-03-29       Impact factor: 2.278

Review 2.  Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.

Authors:  David G Menter; Richard L Schilsky; Raymond N DuBois
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Loss of 15-hydroxyprostaglandin dehydrogenase expression disrupts urothelial differentiation.

Authors:  Stephanie Tseng-Rogenski; I-Ling Lee; Daniel Gebhardt; Susan M Fischer; Christopher Wood; John M Park; Monica Liebert
Journal:  Urology       Date:  2008-02       Impact factor: 2.649

4.  15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.

Authors:  Guosheng Huang; Rosana Eisenberg; Min Yan; Stefano Monti; Earl Lawrence; Pingfu Fu; Jaclyn Walbroehl; Ester Löwenberg; Todd Golub; Jaime Merchan; Daniel G Tenen; Sanford D Markowitz; Balazs Halmos
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 5.  Multifaceted roles of PGE2 in inflammation and cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Semin Immunopathol       Date:  2012-09-21       Impact factor: 9.623

6.  Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis.

Authors:  Manolis Roulis; Christoforos Nikolaou; Elena Kotsaki; Eleanna Kaffe; Niki Karagianni; Vasiliki Koliaraki; Klelia Salpea; Jiannis Ragoussis; Vassilis Aidinis; Eva Martini; Christoph Becker; Harvey R Herschman; Stefania Vetrano; Silvio Danese; George Kollias
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-14       Impact factor: 11.205

7.  IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages.

Authors:  Poonam Kothari; Roberto Pestana; Rim Mesraoua; Rim Elchaki; K M Faisal Khan; Andrew J Dannenberg; Domenick J Falcone
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

8.  Hypoxia activates 15-PGDH and its metabolite 15-KETE to promote pulmonary artery endothelial cells proliferation via ERK1/2 signalling.

Authors:  Cui Ma; Yun Liu; Yanyan Wang; Chen Zhang; Hongmin Yao; Jun Ma; Lei Zhang; Dandan Zhang; Tingting Shen; Daling Zhu
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 9.  Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂.

Authors:  Jessica K Norberg; Earlphia Sells; Hui-Hua Chang; Srinivas R Alla; Shuxing Zhang; Emmanuelle J Meuillet
Journal:  Pharm Pat Anal       Date:  2013-03

10.  Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.

Authors:  Damien Y Duveau; Adam Yasgar; Yuhong Wang; Xin Hu; Jennifer Kouznetsova; Kyle R Brimacombe; Ajit Jadhav; Anton Simeonov; Craig J Thomas; David J Maloney
Journal:  Bioorg Med Chem Lett       Date:  2013-12-04       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.